Quarterly ResultAug 13, 2026, 03:53 PM
EXOZYMES Q2 Net Loss $(2.88)M; Raised $5.86M from Offerings
AI Summary
EXOZYMES INC. reported a net loss of $(2.88) million for the second quarter of 2026 and $(5.25) million for the six months ended June 30, 2026. The net loss per common share was $(0.33) for the quarter and $(0.61) for the six-month period. Despite these losses, the company successfully raised net proceeds of $5.86 million from a public offering and a concurrent registered direct offering of common stock and warrants in June 2026. Management expressed substantial doubt about the company's ability to continue as a going concern due to anticipated funding shortfalls and its pre-revenue status, highlighting the need for additional financial support.
Key Highlights
- Net loss for Q2 2026 was $(2.88) million, compared to $(2.36) million in Q2 2025.
- Net loss for six months ended June 30, 2026, was $(5.25) million, compared to $(4.22) million in 2025.
- Net loss per share for Q2 2026 was $(0.33), compared to $(0.28) in Q2 2025.
- Cash and cash equivalents increased to $5.65 million as of June 30, 2026, from $3.04 million at December 31, 2025.
- Net proceeds from issuance of common stock and warrants totaled $5.86 million for the six months ended June 30, 2026.
- Research and development costs increased to $2.56 million for six months ended June 30, 2026, from $1.38 million in 2025.
- Total liabilities increased to $4.33 million as of June 30, 2026, from $2.57 million at December 31, 2025, including a $1.90 million warrant liability.
Price Impact
More from EXOZ